hyperaldosteronism: Overproduction of aldosterone by the adrenal glands, which may lead to hypokalemia and/or hypernatremia. [ NCIT:P378 ]
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleNone |
519972 |
2. Check conditionsNone |
519972 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
1041 |
4. Check minimum number of eventsNone |
1041 |
5. Include endpointsNone |
1041 |
6. Filter based on genotype QC (FinnGen only) |
1001 |
Control definitions (FinnGen only)
- Control exclude
- E4_ENDOGLAND
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- E20-E35
- Name in latin
- Hyperaldosteronismus
Similar endpoints
↥List of similar endpoints to
Hyperaldosteronism
based on the number of shared cases.
Similar with more cases:
- Disorders of other endocrine glands
- Endocrine, nutritional and metabolic diseases
- Any event in hilmo or specialist outpatient
- Any prescribed medicine buy
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 5523 | 2949 | 2543 |
| Only index persons | 5035 | 2705 | 2330 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.08 | 0.08 | 0.07 |
| Only index persons | 0.09 | 0.10 | 0.09 |
| Median age at first event (years) | |||
| Whole population | 57.31 | 56.48 | 58.24 |
| Only index persons | 56.72 | 55.67 | 57.95 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 1001 | 544 | 457 |
| Unadjusted period prevalence (%) | 0.20 | 0.19 | 0.21 |
| Median age at first event (years) | 57.14 | 55.04 | 59.63 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 1041
- Matched controls
- 10410
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
C03DA01
ATC
spironolactone; oral
69.4
307.7
872
720
E26.0
ICD-10 Finland
Primary hyperaldosteronism
13590.0
307.7
825
*
D35.0
ICD-10 Finland
Benign neoplasm: Adrenal gland
56.6
307.7
227
51
A12BA01
ATC
potassium chloride; oral
19.0
295.3
254
174
BC1AD
NOMESCO Finland
CT of adrenal glands
58.3
294.0
167
34
E87.6
ICD-10 Finland
Hypokalaemia
16.9
265.9
242
183
E26.9
ICD-10 Finland
Hyperaldosteronism, unspecified
+∞
228.8
211
*
205
Kela drug reimbursment
Chronic hypertension
7.2
225.1
631
1839
BC4WT
NOMESCO Finland
Selective blood sample from adrenal gland with radiological guidance
+∞
192.9
179
*
C02AC05
ATC
moxonidine; oral
10.0
158.9
201
244
BCA31
NOMESCO Finland
Endoscopic unilateral adrenalectomy
223.8
151.3
153
8
I15.2
ICD-10 Finland
Hypertension secondary to endocrine disorders
818.7
147.9
142
*
C08CA01
ATC
amlodipine; oral
5.0
136.3
697
3017
E260, I152,
ICD-10 Finland
+∞
131.1
123
*
I15.9
ICD-10 Finland
Secondary hypertension, unspecified
32.5
128.8
84
28
I10
ICD-10 Finland
Essential (primary) hypertension
7.1
117.4
913
5225
BC1CD
NOMESCO Finland
Very extensive CT of adrenal glands
63.6
108.1
60
10
C03EA01
ATC
hydrochlorothiazide and potassium-sparing agents; oral
4.3
93.9
312
937
C08CA13
ATC
lercanidipine; oral
4.1
85.3
303
949
D44.1
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Adrenal gland
20.1
84.6
66
35
C08CA02
ATC
felodipine; oral
4.9
84.6
220
543
Z03.80
ICD-10 Finland
Observation for other suspected diseases and conditions
9.3
79.0
99
116
C08CA05
ATC
nifedipine; systemic
5.2
59.3
134
290
C07AB07
ATC
bisoprolol; oral
2.9
59.0
664
3931
C07AG02
ATC
carvedilol; oral
4.8
56.4
138
319
2551A
ICD-9 Finland
Disorders of adrenal glands, Hyperaldosteronism
+∞
47.2
45
*
E26.8
ICD-10 Finland
Other hyperaldosteronism
+∞
47.2
45
*
E26.1
ICD-10 Finland
Secondary hyperaldosteronism
+∞
45.1
43
*
C09AA02
ATC
enalapril; systemic
2.8
44.6
298
1313
E26
ICD-10 Finland
Hyperaldosteronism
+∞
43.0
41
*
C07AB02
ATC
metoprolol; systemic
2.7
42.8
293
1303
N18.9
ICD-10 Finland
Chronic kidney disease, unspecified
4.3
40.9
113
286
4019X
ICD-9 Finland
Essential hypertension, Unspecified
6.6
40.6
67
107
C09BA02
ATC
enalapril and diuretics; systemic
3.6
40.1
146
449
E11.9
ICD-10 Finland
Type 2 diabetes mellitus, without complications
2.4
36.2
333
1687
C09CA01
ATC
losartan; oral
2.4
35.8
356
1865
XF602
NOMESCO Finland
Bloodpressure monitoring
10.9
35.0
38
36
215
Kela drug reimbursment
Diabetes, non-insulin-treated
2.4
34.6
340
1767
BCA30
NOMESCO Finland
Unilateral adrenalectomy
337.3
33.1
33
*
C08DB01
ATC
diltiazem; oral
4.1
32.5
95
250
103
Kela drug reimbursment
Diabetes, insulin-treated
2.3
32.0
353
1917
C03DB01
ATC
amiloride; oral
47.8
30.8
37
8
A10BA02
ATC
metformin; oral
2.2
30.0
372
2108
C03BA11
ATC
indapamide; oral
5.2
29.4
62
125
C08CA03
ATC
isradipine; systemic
9.5
29.3
35
38
E11
ICD-10 Finland
Type 2 diabetes mellitus
2.5
29.1
227
1054
C02LM02, ,
ATC
8.7
28.9
37
44
C09DA01
ATC
losartan and diuretics; oral
2.7
28.4
168
681
40199
ICD-8 Finland
Essential benign hypertension
7.3
28.1
42
60
E21.0
ICD-10 Finland
Primary hyperparathyroidism
79.9
27.9
31
*
T90
ICPC
Diabetes non-insulin dependent
2.2
27.5
313
1704
K85
ICPC
Elevated blood pressure
2.4
27.5
231
1107
C03AA03
ATC
hydrochlorothiazide; oral
2.9
27.4
138
513
G47.3
ICD-10 Finland
Sleep apnoea
2.2
26.0
299
1629
C09CA06
ATC
candesartan; oral
2.2
25.7
304
1674
C09CA03
ATC
valsartan; oral
2.7
25.7
149
597
C08CA10
ATC
nilvadipine; oral
5.8
25.4
47
84
C02EA02, ,
ATC
4.1
25.2
72
186
25500
ICD-8 Finland
Diseases of adrenal glands, Aldosteronismus. Syndroma Conn
+∞
25.1
24
*
C07FB02
ATC
metoprolol and felodipine; systemic
4.8
25.0
58
127
C07AB08
ATC
celiprolol; oral
5.2
24.2
51
103
I11.9
ICD-10 Finland
Hypertensive heart disease without (congestive) heart failure
3.7
23.2
76
216
C02CA01
ATC
prazosin; oral
7.5
23.0
33
45
N18.8
ICD-10 Finland
Other chronic renal failure
5.6
22.8
44
82
E21.09
ICD-10 Finland
Other primary hyperparathyroidism
85.4
22.8
25
*
FM1AE
NOMESCO Finland
Standard cardiac ultrasound examination
2.2
22.7
239
1250
C09DA06
ATC
candesartan and diuretics; oral
2.9
22.3
116
437
E11.2
ICD-10 Finland
Type 2 diabetes mellitus, with renal complications
4.2
22.2
61
153
C09CA07
ATC
telmisartan; oral
2.9
22.1
110
405
C02DE02, ,
ATC
7.4
21.3
31
43
C03CA01
ATC
furosemide; systemic
1.9
20.6
334
2036
C09DA07
ATC
telmisartan and diuretics; oral
3.7
20.4
66
186
A10BH05
ATC
linagliptin; oral
3.2
20.3
83
272
C07AB03
ATC
atenolol; systemic
3.2
20.3
86
288
207
Kela drug reimbursment
Chronic arrhythmias
2.2
20.2
200
1016
C02DE10, ,
ATC
7.4
20.0
29
40
E34.9
ICD-10 Finland
Endocrine disorder, unspecified
+∞
19.9
19
*
ZXD10
NOMESCO Finland
Scheduled procedure
1.8
19.5
427
2855
GD1AA
NOMESCO Finland
Thorax X-ray examination
1.8
19.5
522
3710
O10.0
ICD-10 Finland
Pre-existing essential hypertension complicating pregnancy, childbirth and the puerperium
8.5
19.3
25
30
ZXE10
NOMESCO Finland
More than one and less than three hours
1.8
19.1
404
2669
SPAT1262
SPAT
Handing over of treatment supplies
2.1
18.8
218
1175
123
Kela drug reimbursment
Chronic disorders of vitamin D metabolism
5.2
18.5
38
75
285
Kela drug reimbursment
Dulaglutide, exenatide, liraglutide, lixisenatide and semaglutide (adults)
2.9
18.5
90
327
A11CC03
ATC
alfacalcidol; systemic
5.1
18.4
39
79
WX402
NOMESCO Finland
General anaesthesia
2.0
18.0
246
1404
C09DB01
ATC
valsartan and amlodipine; oral
3.6
17.8
59
169
Z3231
NOMESCO Finland
Registered nurse
1.9
17.8
305
1877
I15.8
ICD-10 Finland
Other secondary hypertension
23.2
17.8
25
11
BC1BD
NOMESCO Finland
Extensive CT of adrenal glands
67.8
17.8
20
*
A10BJ06
ATC
semaglutide; parenteral
3.1
17.6
76
258
ZXE00
NOMESCO Finland
One hour or less
1.8
17.0
422
2898
E66.00
ICD-10 Finland
Metabolic syndrome
2.9
16.8
81
292
K86
ICPC
Hypertension uncomplicated
2.2
16.8
165
831
346
Kela drug reimbursment
Dulaglutide, exenatide, liraglutide, lixisenatide and semaglutide (adults)
2.9
16.3
82
303
A12AA04
ATC
calcium carbonate; oral
6.6
16.3
26
40
E11.8
ICD-10 Finland
Type 2 diabetes mellitus, with unspecified complications
2.3
16.0
140
672
E21.3
ICD-10 Finland
Hyperparathyroidism, unspecified
61.0
15.8
18
*
N08.39*E11.2
ICD-10 Finland
Non-insulin-dependent diabetes mellitus - Diabetic nephropathy
5.6
15.3
29
53
A10BK03
ATC
empagliflozin; oral
2.2
15.2
133
638
C08DA01
ATC
verapamil; systemic
3.1
15.0
63
210
SPAT1250
SPAT
Comprehensive monitoring of chronic illness
1.8
15.0
299
1913
B01AA03
ATC
warfarin; systemic
1.9
14.9
210
1203
A10BH01
ATC
sitagliptin; oral
2.3
14.9
123
577
H02AB09
ATC
hydrocortisone; systemic
5.4
14.7
29
55
BBA30
NOMESCO Finland
Excision of lesion of parathyroid gland
+∞
14.6
14
*
Z2221
NOMESCO Finland
Medical doctor
1.8
14.3
296
1909
PC5CG
NOMESCO Finland
Extensive MRI examination of kidney vasculature with high intensity magnet
43.1
14.1
17
*
I48
ICD-10 Finland
Atrial fibrillation and flutter
1.8
13.8
241
1476
TFP20
NOMESCO Finland
Cardiodefibrillation
2.4
13.8
99
436
PG1DE
NOMESCO Finland
Other extensive ultrasound examination of artery
2.9
13.6
64
228
2533
FHL
Unilateral removal of additional egg
+∞
13.6
13
*
I152, E260,
ICD-10 Finland
+∞
13.6
13
*
R4110
NOMESCO Finland
Physiotherapy
1.7
13.1
300
1985
E11.7
ICD-10 Finland
Type 2 diabetes mellitus, with multiple complications
2.7
13.0
71
274
TPH04
NOMESCO Finland
Cathetrisation of vein
1.8
12.8
241
1508
351
Kela drug reimbursment
Apixaban, dabigatran, edoxaban and rivaroxaban for the treatment of atrial fibrillation
1.9
12.7
173
976
R06.0
ICD-10 Finland
Dyspnoea
1.7
12.7
289
1905
C02DE04, ,
ATC
4.2
12.6
33
80
XF400
NOMESCO Finland
ECG with 12 standard connections
1.9
12.6
176
1003
290
Kela drug reimbursment
Apixaban, dabigatran, edoxaban and rivaroxaban for the treatment of atrial fibrillation
1.9
12.6
191
1118
A10AE04
ATC
insulin glargine; parenteral
2.2
12.4
114
558
XF404
NOMESCO Finland
Ambulatory ECG
2.2
12.4
110
531
C07BB07
ATC
bisoprolol and thiazides; systemic
3.0
12.2
54
186
C09DA03
ATC
valsartan and diuretics; oral
2.7
12.1
67
260
R10.4
ICD-10 Finland
Other and unspecified abdominal pain
1.6
12.1
358
2521
TPH07
NOMESCO Finland
Cathetrisation of artery
2.0
12.1
133
697
M04AA01
ATC
allopurinol; systemic
2.0
12.0
146
792
C07AB04
ATC
acebutolol; systemic
4.8
11.9
27
58
E87.5
ICD-10 Finland
Hyperkalaemia
4.4
11.7
29
67
C09DX01
ATC
valsartan, amlodipine and hydrochlorothiazide; oral
3.9
11.7
34
89
E66.01
ICD-10 Finland
Obesity due to excess calories
2.3
11.7
95
442
E66.8
ICD-10 Finland
Other obesity
2.7
11.5
62
238
B01AF02
ATC
apixaban; oral
2.0
11.4
143
783
C07AB12
ATC
nebivolol; oral
3.1
11.4
47
155
R5140
NOMESCO Finland
Monitoring the use of the aid
2.0
11.2
131
701
P06
ICPC
Sleep disturbance
2.0
11.2
126
665
C07AB05
ATC
betaxolol; oral
3.5
11.2
39
116
R53
ICD-10 Finland
Malaise and fatigue
1.7
11.1
246
1604
U14
ICPC
Kidney symptom/complaint
5.1
11.0
23
46
R07.4
ICD-10 Finland
Chest pain, unspecified
1.6
10.9
301
2075
Z3226
NOMESCO Finland
Physiotherapist
1.8
10.8
192
1174
WX110
NOMESCO Finland
Infiltration anesthesia
1.6
10.8
711
5979
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
2.1
10.8
110
559
WX404
NOMESCO Finland
Intravenous generell anesthesy
1.7
10.8
215
1359
I50.9
ICD-10 Finland
Heart failure, unspecified
1.9
10.7
142
794
M10.9
ICD-10 Finland
Gout, unspecified
2.3
10.6
82
373
I11.0
ICD-10 Finland
Hypertensive heart disease with (congestive) heart failure
3.4
10.6
38
115
R04.0
ICD-10 Finland
Epistaxis
2.2
10.6
92
440
J01MA02
ATC
ciprofloxacin; systemic
1.6
10.5
391
2889
E24.8
ICD-10 Finland
Other Cushing syndrome
+∞
10.4
10
*
D35.2
ICD-10 Finland
Benign neoplasm: Pituitary gland
16.2
10.4
16
10
R60.0
ICD-10 Finland
Localized oedema
1.9
10.2
129
709
WX408
NOMESCO Finland
General anesthesy, balanced
1.6
10.1
267
1814
N02BE01
ATC
paracetamol; systemic, rectal
1.9
10.1
922
8349
A10AB05
ATC
insulin aspart; parenteral
2.2
10.1
84
394
XF603
NOMESCO Finland
Direct intraarterial blood pressure measurement
2.8
10.1
49
178
K87
ICPC
Hypertension complicated
3.3
10.1
37
114
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
1.6
9.7
331
2388
I15.1
ICD-10 Finland
Hypertension secondary to other renal disorders
5.1
9.6
20
40
N19
ICD-10 Finland
Unspecified kidney failure
2.9
9.6
44
155
R55
ICD-10 Finland
Syncope and collapse
1.9
9.5
121
665
R35
ICD-10 Finland
Polyuria
2.2
9.5
80
377
A91
ICPC
Abnormal result investigation NOS
2.4
9.5
64
274
QBE10
NOMESCO Finland
Excision of other lesion extending through all layers of skin of trunk
2.2
9.5
78
365
I15
ICD-10 Finland
Secondary hypertension
30.3
9.4
12
*
321
Kela drug reimbursment
Paricalcitol and cinacalcet
30.3
9.4
12
*
I48.1
ICD-10 Finland
Persistent atrial fibrillation
2.7
9.3
48
180
C03EA02
ATC
trichlormethiazide and potassium-sparing agents; oral
4.0
9.2
26
67
C02EA03, ,
ATC
4.3
9.2
23
54
KA1AE
NOMESCO Finland
Kidney ultrasound examination
3.2
9.1
35
111
JN1CD
NOMESCO Finland
Very extensive CT examination of upper part of abdomen
8.4
9.1
19
23
C10AA01
ATC
simvastatin; oral
1.5
9.1
433
3349
A10BB12
ATC
glimepiride; oral
2.2
9.1
77
365
I12.0
ICD-10 Finland
Hypertensive renal disease with renal failure
7.1
9.0
21
30
JN3AD
NOMESCO Finland
Abdominal CT examination
1.9
8.9
123
694
A02BC02
ATC
pantoprazole; systemic
1.5
8.8
685
5833
JN1AE
NOMESCO Finland
Ultrasound examination of upper part of abdomen
2.0
8.7
98
517
XF600
NOMESCO Finland
Bloodpressure measurement
2.3
8.7
69
318
I48.0
ICD-10 Finland
Paroxysmal atrial fibrillation
2.0
8.7
94
489
T81.0
ICD-10 Finland
Haemorrhage and haematoma complicating a procedure, not elsewhere classified
2.2
8.6
69
319
D41.0
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Kidney
3.0
8.6
38
131
N02AX02
ATC
tramadol; systemic, rectal
1.5
8.6
432
3364
Z01.8
ICD-10 Finland
Other specified special examinations
1.6
8.6
224
1512
C09BA03
ATC
lisinopril and diuretics; oral
3.2
8.6
33
105
N05BA04
ATC
oxazepam; oral
1.6
8.4
257
1798
N02AE01
ATC
buprenorphine; parenteral, sublingual, transdermal
1.8
8.4
143
862
D350, E260,
ICD-10 Finland
+∞
8.3
8
*
101
Kela drug reimbursment
Anterior pituitary hypofunction
+∞
8.3
8
*
C73.91
ICD-10 Finland
Papillary carcinoma of the thyroid gland (thyroid gland)
4.3
8.2
21
50
138
Kela drug reimbursment
Severe anaemia associated with chronic renal failure
3.6
8.2
26
73
FM1EE
NOMESCO Finland
Extensive structural and functional ultrasound examination of heart
1.6
8.1
245
1709
C09CA08
ATC
olmesartan medoxomil; oral
3.4
8.1
28
83
I48.9
ICD-10 Finland
Atrial fibrillation and atrial flutter, unspecified
2.1
8.1
75
368
K76.0
ICD-10 Finland
Fatty (change of) liver, not elsewhere classified
3.0
8.0
34
115
E78.9
ICD-10 Finland
Disorder of lipoprotein metabolism, unspecified
2.7
7.9
43
166
RD210, ,
NOMESCO Finland
4.5
7.9
19
43
FN1AC
NOMESCO Finland
Angiography of heart and/or coronary arteries
1.6
7.6
236
1655
ZXA10
NOMESCO Finland
Bilateral
1.6
7.6
187
1242
A09
ICD-10 Finland
Other gastroenteritis and colitis of infectious and unspecified origin
1.7
7.6
164
1054
H05BX01
ATC
cinacalcet; oral
25.2
7.6
10
*
WX892
NOMESCO Finland
Monitored bed care
2.0
7.5
82
428
N06AA09
ATC
amitriptyline; systemic
1.9
7.5
99
552
UJF30
NOMESCO Finland
Ileoscopy through colon
1.8
7.5
105
597
Z49.1
ICD-10 Finland
Extracorporeal dialysis
4.4
7.4
18
41
PBL10
NOMESCO Finland
Construction of arteriovenous fistula from radial artery
6.5
7.4
18
28
C07AA07
ATC
sotalol; systemic
2.6
7.4
41
160
A06AC01
ATC
ispaghula (psylla seeds); oral
1.5
7.4
262
1889
XKD00
NOMESCO Finland
Uroflowmetry
1.7
7.4
155
988
C03EB01
ATC
furosemide and potassium-sparing agents; systemic
2.6
7.3
40
155
I50
ICD-10 Finland
Heart failure
2.8
7.3
36
132
R02
ICPC
Shortness of breath/dyspnoea
1.7
7.3
128
776
J01DB01
ATC
cefalexin; oral
1.5
7.3
824
7405
E23.00
ICD-10 Finland
Panhypopituitarism
+∞
7.3
7
*
R5110
NOMESCO Finland
Evaluation of the need for aids, the testing, fitting and choice of the aid, instruction in use and delivery of it
1.7
7.2
129
787
C09AA04
ATC
perindopril; oral
2.3
7.2
55
250
K78
ICPC
Atrial fibrillation/flutter
1.9
7.1
83
443
WX723
NOMESCO Finland
CPAP therapy
2.5
7.1
45
188
KE1BE
NOMESCO Finland
Rectal ultrasound examinaiton of prostata
1.9
7.1
91
503
S18
ICPC
Laceration/cut
1.4
7.0
452
3647
Z71.8
ICD-10 Finland
Other specified counselling
1.5
7.0
286
2118
JKA21
NOMESCO Finland
Laparoscopic cholecystectomy
1.8
7.0
108
632
Z71.3
ICD-10 Finland
Dietary counselling and surveillance
2.4
7.0
46
196
N17.9
ICD-10 Finland
Acute renal failure, unspecified
2.5
6.9
44
184
H03AA01
ATC
levothyroxine sodium; systemic
1.5
6.9
215
1504
C09AA03
ATC
lisinopril; oral
2.3
6.9
53
241
Z3229
NOMESCO Finland
Other healthcare associate professional
1.9
6.9
84
456
WZC00
NOMESCO Finland
Treatment plan or consultation
1.4
6.9
340
2615
TK800
NOMESCO Finland
Hemodialysis
3.3
6.7
25
78
C10AA05
ATC
atorvastatin; oral
1.4
6.7
419
3356
J45.9
ICD-10 Finland
Asthma, unspecified
1.6
6.7
181
1228
N18.5
ICD-10 Finland
Chronic kidney disease, stage 5
7.9
6.6
14
18
C07AG01
ATC
labetalol; systemic
5.9
6.6
17
29
N62
ICD-10 Finland
Hypertrophy of breast
2.5
6.5
41
171
N06CA01
ATC
amitriptyline and psycholeptics; systemic
1.8
6.5
100
584
WX002
NOMESCO Finland
Sedation and analgesia
1.5
6.5
191
1319
G04CA02
ATC
tamsulosin; oral
1.5
6.5
226
1620
E78.29
ICD-10 Finland
Other mixed hyperlipidaemia
5.7
6.5
17
30
E89.01
ICD-10 Finland
Postsurgical hypothyroidism
3.4
6.4
22
65
D07AC01
ATC
betamethasone; topical
1.4
6.4
339
2630
E21.2
ICD-10 Finland
Other hyperparathyroidism
70.3
6.4
7
*
F32.2
ICD-10 Finland
Severe depressive episode without psychotic symptoms
2.0
6.4
64
324
M54.5
ICD-10 Finland
Low back pain
1.4
6.4
340
2643
C02DE12, ,
ATC
6.0
6.3
16
27
AA4CG
NOMESCO Finland
Extensive MRI examination of sella turcica with high intensity magnet
11.1
6.3
11
10
PC5DE
NOMESCO Finland
Ultrasound of kidney circulation with Doppler technic
9.3
6.3
12
13
S29
ICPC
Skin symptom/complaint other
1.6
6.3
177
1211
C10AA07
ATC
rosuvastatin; oral
1.4
6.3
314
2413
BBA20
NOMESCO Finland
Exploration of parathyroid gland
+∞
6.3
6
*
E260, D350,
ICD-10 Finland
+∞
6.3
6
*
V03AE02
ATC
sevelamer; oral
12.6
6.1
10
8
A10BJ02
ATC
liraglutide; parenteral
2.6
6.1
34
134
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
1.6
6.0
159
1070
C09AA05
ATC
ramipril; oral
1.5
6.0
252
1869
N03AX16
ATC
[U] pregabalin
1.5
6.0
223
1615
J34.1
ICD-10 Finland
Cyst and mucocele of nose and nasal sinus
3.5
6.0
20
58
J01FA06
ATC
roxithromycin; oral
1.4
6.0
376
2999
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
333
89
54.54
307.65
2.9
1.2
1319.01
305.92
pmol/l
1.99
321
83
241
34
91.93
307.65
1.4
1.2
183.15
159.17
mmol/24h
0.81
241
34
196
93
25.73
268.75
1.2
1.2
0.56
0.57
nmol/l
0.21
185
86
192
93
25.09
260.88
1.2
1.2
0.37
0.42
nmol/l
—
9
5
166
79
24.81
226.42
1.2
1.2
—
—
nmol/l
—
0
0
84
25
36.46
133.29
1.7
1.1
776.03
373.94
pmol/l
2.87
62
17
297
740
5.22
115.40
2.4
2.0
321.54
376.00
nmol/l
3.78
281
684
78
30
28.02
113.96
1.6
1.4
3.59
1.48
nmol/l
0.83
66
25
63
16
41.85
103.92
1.6
1.1
87.59
66.38
nmol/24h
0.84
63
16
396
1386
4.00
96.63
3.0
3.3
0.82
0.82
mmol/l
0.10
374
1313
723
4315
3.21
66.49
9.1
6.7
1.21
1.21
mmol/l
0.56
607
3699
667
3928
2.94
60.42
8.7
5.9
1.21
1.21
mmol/l
0.42
637
3591
525
2777
2.80
57.57
4.6
3.7
14.25
8.30
mg/mmol
1.75
346
1775
499
2625
2.73
54.51
3.8
3.2
76.06
285.50
mg/l
2.21
339
1708
512
2759
2.68
52.85
3.7
3.1
7.32
7.69
mmol/l
1.06
442
2321
273
1101
3.01
48.60
8.4
5.6
1.05
1.04
mmol/l
0.14
257
1021
181
586
3.53
46.31
5.7
3.3
108.80
81.44
ng/l
3.22
162
516
636
4153
2.37
38.99
19.9
15.4
1.23
1.27
inr
0.74
282
1189
432
2427
2.33
37.27
3.7
3.1
0.45
0.47
e6/l
0.05
332
1847
457
2634
2.31
37.07
3.7
3.2
35.26
92.57
e6/l
1.22
360
2031
577
3740
2.22
34.28
5.6
4.8
36.21
35.46
g/l
2.94
536
3493
501
3071
2.22
34.22
4.3
3.6
123.85
98.25
e6/l
0.11
377
2191
332
1828
2.20
28.53
3.0
2.5
3.84
5.61
e6/l
2.19
303
1649
702
5168
2.10
27.02
6.1
4.9
7.08
6.73
mmol/l
3.38
672
4863
177
759
2.60
26.68
10.5
7.1
11.10
9.71
mmol/l
1.34
168
727
82
228
3.82
25.90
2.9
3.6
1.64
1.58
mg/l
0.18
73
209
51
97
5.48
25.81
1.7
1.7
5.41
4.55
mmol/24h
0.87
46
90
371
2204
2.06
25.62
4.0
4.0
88.26
89.67
%
0.43
365
2151
181
802
2.52
25.41
5.0
3.6
1.84
2.05
mmol/l
0.25
157
650
180
810
2.48
24.39
5.1
3.6
5.88
5.82
kpa
0.33
175
785
513
3495
1.92
23.24
2.9
2.1
75.87
76.90
nmol/l
0.36
470
3100
837
6765
2.21
22.84
8.6
7.5
76.72
78.41
u/l
0.63
811
6364
370
2313
1.93
21.26
3.1
2.6
4374.13
7045.40
umol/l
0.52
316
2018
949
8175
2.82
21.17
8.2
5.8
41.50
39.96
mmol/mol
4.57
899
7582
814
6612
2.06
20.36
4.8
3.8
15.00
14.80
pmol/l
1.45
749
6006
439
2940
1.85
20.10
3.4
3.4
2.35
2.35
mmol/l
0.21
394
2583
64
180
3.72
19.86
5.9
4.0
3.15
2.62
mmol/l
0.60
47
122
892
7527
2.29
19.82
24.5
17.2
14.82
15.04
%
0.52
882
7407
563
4111
1.80
19.04
6.4
5.9
59.29
57.47
%
3.43
535
3856
149
687
2.36
18.88
5.9
3.7
1.22
1.22
mmol/l
0.57
139
596
568
4166
1.80
18.85
6.5
6.1
26.16
27.48
%
2.35
540
3908
223
1222
2.05
18.34
4.2
2.4
2.30
2.31
g/l
0.14
209
1134
212
1142
2.08
18.25
4.4
2.4
23.47
22.98
%
0.19
188
982
923
7979
2.38
18.05
5.9
4.6
1.96
1.93
mu/l
0.32
864
7294
235
1324
2.00
17.84
4.1
2.4
13.21
13.11
umol/l
0.07
224
1234
573
4273
1.76
17.41
5.7
4.9
0.00
0.00
estimate
0.50
149
777
649
5024
1.77
17.22
8.4
9.3
4.49
4.13
e9/l
3.52
565
4404
607
4610
1.76
17.21
5.6
6.4
12.02
11.43
umol/l
0.37
575
4394
278
1689
1.88
16.74
4.3
3.9
624.75
332.40
ng/l
0.26
229
1333
573
4324
1.72
16.22
4.5
3.6
0.00
0.00
estimate
0.50
139
750
568
4278
1.72
16.18
4.5
3.6
0.00
0.00
estimate
0.50
153
832
254
1515
1.89
16.11
3.0
2.7
0.75
1.13
e6/l
1.76
134
882
240
1408
1.92
16.00
3.1
2.9
1.84
2.20
e6/l
0.28
120
780
782
6469
1.84
15.80
4.8
4.0
13.50
12.35
mm/h
1.10
738
5972
381
2590
1.74
15.58
3.4
3.0
1740.20
1195.65
ng/l
1.22
324
2234
996
9055
3.31
15.31
30.2
16.5
139.57
139.68
mmol/l
0.62
985
8821
939
8306
2.33
15.19
23.6
13.2
74.19
80.27
ml/min/173m2
12.17
837
6861
996
9082
3.24
14.68
31.6
16.7
3.87
3.98
mmol/l
21.59
985
8838
358
2425
1.73
14.62
1.8
1.7
1.60
1.38
mmol/l
2.95
304
2037
965
8682
2.53
14.23
20.5
14.4
21.33
24.52
mg/l
2.62
823
6903
135
675
2.15
13.92
4.2
2.9
4.96
4.54
kpa
1.38
129
651
402
2872
1.65
13.10
2.9
3.3
30.88
33.80
u/l
0.61
378
2734
458
3387
1.63
12.97
4.5
3.6
40.96
49.40
ng/l
0.26
339
2401
140
731
2.06
12.85
2.4
3.0
66.49
66.71
g/l
0.13
125
672
952
8580
2.28
12.85
6.0
4.6
6.32
5.97
mmol/l
9.65
892
7826
32
75
4.37
12.72
2.1
2.3
—
—
—
0
0
696
5736
1.64
12.40
5.6
4.4
579.00
3030.15
e6/l
—
6
93
151
824
1.97
12.24
2.6
2.5
31.43
41.60
u/l
1.04
129
705
112
556
2.14
11.72
4.4
3.6
5.09
5.16
kpa
0.34
105
541
52
180
2.99
11.64
3.0
2.6
18.34
15.89
%
3.47
33
100
98
463
2.23
11.60
3.0
3.2
4.25
4.48
pmol/l
1.61
88
412
107
524
2.16
11.59
4.4
3.6
2.40
1.78
mmol/l
0.66
73
406
474
3602
1.58
11.56
2.2
2.0
94.09
95.58
pmol/l
0.29
251
1894
251
1634
1.71
11.40
3.3
3.1
2.44
2.45
mmol/l
0.29
217
1436
121
626
2.06
11.35
2.5
2.1
11.99
12.84
nmol/l
0.21
105
559
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
67
270
2.58
11.28
2.6
2.5
0.33
0.35
u/ml
0.18
36
152
371
2684
1.59
11.04
2.3
2.1
179.09
235.91
u/l
0.85
352
2535
59
229
2.67
10.71
2.7
3.0
24.15
25.00
mmol/l
0.73
59
224
164
971
1.82
10.27
2.6
4.4
233.28
252.25
u/l
0.95
148
918
169
1015
1.79
10.09
8.4
8.2
5.25
5.12
kpa
0.93
163
973
169
1015
1.79
10.09
8.4
8.2
12.13
12.14
kpa
0.01
163
974
130
738
1.87
9.28
2.7
3.0
277.14
188.29
ng/l
0.77
124
678
49
187
2.70
9.22
1.9
2.3
138.55
129.35
g/l
1.51
38
141
466
3650
1.50
9.21
4.1
2.7
147.63
135.14
ug/l
0.67
432
3371
277
1938
1.58
9.20
1.8
1.7
0.88
1.17
mg/l
1.65
208
1489
104
552
1.98
9.07
3.7
3.4
133.49
128.06
g/l
1.50
104
542
165
1019
1.74
8.90
8.6
8.2
1.28
1.25
mmol/l
0.03
135
802
314
2300
1.52
8.38
5.0
3.9
0.01
0.01
estimate
0.08
140
746
291
2105
1.53
8.20
1.7
1.5
18.27
20.77
nmol/l
2.70
263
1779
63
288
2.26
8.10
2.3
4.0
36.02
61.42
mg/l
0.62
50
235
955
8873
1.92
7.89
6.2
5.0
2.56
2.75
mmol/l
8.37
888
8169
989
9312
2.24
7.74
13.6
10.5
33.09
26.45
u/l
0.77
967
8974
62
288
2.23
7.68
2.4
4.0
43.01
72.46
mg/l
0.72
49
234
361
2762
1.47
7.64
2.8
2.6
58.46
60.79
u/l
0.33
329
2558
419
3305
1.45
7.54
4.8
3.8
—
—
—
0
0
506
4142
1.43
7.40
2.6
2.6
—
—
—
0
0
934
8654
1.77
7.29
5.5
4.4
1.31
1.46
mmol/l
23.97
865
7955
51
224
2.34
7.21
2.6
2.4
130.22
76.48
ug/min
0.44
30
138
251
1809
1.51
7.06
1.2
1.2
0.95
1.61
u/ml
0.90
69
490
209
1454
1.55
6.91
1.9
1.9
—
—
—
0
0
937
8715
1.75
6.88
5.5
4.5
4.37
4.64
mmol/l
13.35
878
8065
143
909
1.66
6.87
4.8
3.2
—
—
—
0
0
906
8354
1.65
6.85
4.8
4.0
1.53
1.31
mmol/l
10.72
831
7630
153
993
1.63
6.78
2.7
2.7
7.01
8.42
umol/l
0.45
127
866
95
540
1.84
6.75
1.6
1.7
—
—
—
0
0
15
21
7.23
6.71
1.0
1.1
0.60
0.73
umol/24h
—
7
13
288
2158
1.46
6.62
2.5
2.1
2.88
3.04
mg/l
0.58
247
1842
63
313
2.08
6.62
2.3
2.6
10.34
10.46
g/l
0.07
55
284
227
1625
1.51
6.54
1.4
1.5
2.47
2.54
g/l
0.24
130
997
41
172
2.44
6.44
1.8
1.2
9.86
9.41
u/l
0.07
36
135
148
968
1.62
6.35
2.3
2.7
1.93
1.81
%
0.85
132
871
51
239
2.19
6.23
2.3
2.8
0.00
0.00
g/l
-0.00
45
222
43
188
2.34
6.18
1.3
1.6
1.38
0.86
nmol/l
1.02
31
158
69
368
1.94
5.98
2.1
2.0
42.28
39.91
u/l
0.48
58
328
36
148
2.48
5.92
2.6
1.6
191.77
218.96
pmol/l
0.90
31
133
95
565
1.75
5.83
12.2
10.2
0.67
0.67
%
0.01
95
560
64
337
1.96
5.76
2.3
2.5
3.66
3.69
g/l
0.08
56
310
64
338
1.95
5.71
2.3
2.5
7.57
7.47
g/l
0.18
57
310
64
338
1.95
5.71
2.3
2.5
—
—
—
0
0
151
1017
1.57
5.71
1.6
1.8
—
—
—
0
0
72
396
1.88
5.70
1.7
1.9
1.56
1.57
g/l
0.02
62
345
52
256
2.09
5.63
2.3
2.8
0.00
0.00
g/l
0.50
46
238
94
567
1.72
5.49
12.1
10.0
1.19
1.33
%
0.84
94
562
129
849
1.59
5.38
2.1
2.2
0.23
0.21
g/l
1.32
115
795
150
1030
1.53
5.20
1.7
1.8
—
—
—
0
0
52
265
2.01
5.16
2.3
2.6
36.24
37.46
g/l
0.76
45
237
25
92
2.76
5.13
1.2
1.2
49.48
49.59
u/l
0.01
19
85
654
5783
1.35
5.12
3.5
3.1
50.12
50.97
u/l
0.11
625
5376
17
53
3.24
4.63
1.2
1.1
88.25
78.32
u/l
0.33
12
47
54
291
1.90
4.59
2.3
3.0
0.30
1.52
g/l
3.00
46
259
30
133
2.29
4.25
1.2
1.3
—
—
—
0
0
16
51
3.17
4.22
1.3
1.1
19.91
15.89
u/l
0.27
11
44
55
312
1.81
4.02
2.2
2.0
617.76
410.70
ug/l
0.45
50
290
28
127
2.24
3.79
1.0
1.1
4.00
29.03
iu/ml
—
6
28
103
700
1.52
3.76
2.7
2.6
57.59
66.96
ml/min/173m2
1.88
64
272
27
121
2.26
3.76
1.3
1.2
1.33
4.19
u/ml
—
9
37
999
9665
1.83
3.72
32.1
21.3
40.79
40.17
%
2.71
945
9001
999
9670
1.82
3.64
31.6
21.2
251.12
248.22
e9/l
0.71
982
9427
54
315
1.75
3.62
2.4
2.6
3.09
3.03
g/l
0.16
47
287
7
9
7.82
3.56
1.3
1.0
—
—
—
0
0
999
9675
1.81
3.56
31.7
21.2
4.58
4.49
e12/l
7.05
978
9409
999
9678
1.80
3.51
31.9
21.3
137.45
135.61
g/l
3.51
992
9529
134
979
1.42
3.41
2.5
2.2
133.52
129.70
ug/g
0.03
104
790
209
1646
1.34
3.36
2.0
1.7
1219.34
1195.09
nmol/l
0.12
159
1245
26
121
2.18
3.34
1.3
1.2
2.90
4.67
u/ml
—
10
46
54
323
1.71
3.34
1.3
1.5
—
155.38
—
0
13
233
1867
1.32
3.32
3.4
3.0
0.77
0.74
ug/l
0.21
165
1211
579
5195
1.26
3.31
2.8
2.8
—
—
—
0
0
44
249
1.80
3.29
1.2
1.2
—
—
—
0
0
44
249
1.80
3.29
1.2
1.2
—
—
—
0
0
263
2146
1.30
3.28
2.3
2.3
—
—
—
0
0
41
229
1.82
3.20
1.3
1.2
—
—
—
0
0
35
186
1.91
3.18
1.4
1.3
—
—
—
0
0
35
186
1.91
3.18
1.4
1.3
—
—
—
0
0
44
252
1.78
3.17
2.2
2.7
3.68
3.67
g/l
0.01
44
239
109
793
1.42
2.86
2.4
2.4
12.18
6.74
ug/l
0.55
92
706
14
53
2.66
2.80
1.1
1.2
—
—
—
0
0
18
78
2.33
2.75
2.4
2.2
—
—
—
0
0
34
189
1.83
2.73
1.5
2.2
2033.97
3171.84
u/l
—
7
67
7
14
5.03
2.73
1.0
1.2
1.95
1.94
umol/24h
—
7
14
31
169
1.86
2.65
3.2
3.8
57.29
57.86
%
0.07
31
169
54
345
1.60
2.65
6.2
4.0
25.20
24.87
mmol/l
0.26
48
333
228
1875
1.28
2.64
1.8
1.7
107527314.80
21694912.12
pmol/l
0.50
186
1558
30
163
1.87
2.60
3.2
3.4
3.95
4.20
e9/l
0.28
30
163
22
108
2.06
2.53
1.2
1.0
—
—
—
0
0
41
249
1.67
2.46
2.6
1.7
—
—
—
0
0
53
345
1.56
2.42
3.6
3.4
2296.67
4154.22
u/ml
0.21
46
294
39
235
1.69
2.42
1.5
2.1
12.05
11.92
mg/l
0.03
31
218
87
629
1.42
2.39
1.6
1.7
—
—
—
0
0
9
27
3.35
2.39
1.7
1.9
—
—
—
0
0
5
8
6.27
2.37
10.0
5.9
5.60
5.76
mmol/l
—
5
8
21
104
2.04
2.37
1.3
2.4
33.48
32.69
pg
0.34
21
104
166
1330
1.30
2.35
1.3
1.5
—
—
—
0
0
173
1398
1.28
2.30
1.3
1.3
17.52
12.12
u/ml
0.24
57
535
16
72
2.24
2.28
1.0
1.1
—
—
—
0
0
7
18
3.91
2.25
1.0
1.0
—
—
—
0
0
180
1467
1.27
2.24
1.3
1.3
36.88
34.80
iu/ml
0.06
53
485
11
41
2.70
2.21
1.3
1.1
1.03
1.07
ratio
—
5
16
11
43
2.57
2.08
1.0
1.1
—
—
—
0
0
14
62
2.28
2.08
1.1
1.1
—
—
—
0
0
14
62
2.28
2.08
1.1
1.1
—
—
—
0
0
33
199
1.68
2.07
3.2
3.2
0.84
0.83
nmol/l
0.03
27
160
74
535
1.41
2.07
1.2
1.2
145.98
143.55
iu/ml
0.02
24
218
14
63
2.24
2.01
1.1
1.1
—
—
—
0
0
14
63
2.24
2.01
1.1
1.1
—
—
—
0
0
14
63
2.24
2.01
1.1
1.1
—
—
—
0
0
6
16
3.77
1.93
1.2
1.2
100.83
90.00
%
—
6
16
33
204
1.64
1.91
1.5
1.8
4.88
5.49
iu/l
0.08
11
61
292
2562
1.19
1.79
4.6
4.2
23.55
20.83
%
2.27
151
1215
40
265
1.53
1.76
1.9
1.7
—
—
—
0
0
12
54
2.24
1.74
1.2
1.4
14.75
13.20
u/l
0.18
12
49
353
3158
1.18
1.73
5.5
4.9
2.47
2.45
ug/l
0.02
324
2836
0
46
0.00
1.71
0.0
1.2
—
—
—
0
0
70
521
1.37
1.69
1.5
1.4
—
—
—
0
0
35
230
1.54
1.61
1.7
1.3
—
—
—
0
0
38
255
1.51
1.60
1.6
1.6
0.02
0.08
iu/ml
—
9
48
40
272
1.49
1.58
1.4
1.4
286.82
280.82
ug/g
0.05
22
162
33
215
1.55
1.58
1.5
1.8
5617.58
15696.03
e6/l
1.85
19
163
56
407
1.40
1.57
1.3
1.3
—
—
—
0
0
16
85
1.90
1.55
1.1
1.1
—
—
—
0
0
14
71
1.99
1.54
1.2
1.8
—
—
—
0
0
7
27
2.60
1.51
1.6
1.3
45.14
61.84
ug/l
—
7
27
11
51
2.17
1.51
2.3
1.5
9.52
6.36
ug/l
0.48
11
43
9
37
2.44
1.48
1.2
1.1
—
—
—
0
0
51
370
1.40
1.46
1.8
2.0
1.32
2.21
ug/l
0.48
44
334
53
708
0.74
1.39
1.6
1.7
—
—
—
0
0
9
41
2.21
1.37
1.9
3.1
449.44
1245.10
u/ml
—
9
41
126
1047
1.23
1.37
1.8
1.8
1.54
1.51
%
0.11
108
909
19
112
1.71
1.36
1.1
1.1
—
—
—
0
0
29
191
1.53
1.36
1.4
1.4
—
—
—
0
0
54
406
1.35
1.27
1.1
1.0
—
—
—
0
0
114
948
1.23
1.24
3.3
4.3
10.48
28.33
ug/l
1.09
84
800
23
148
1.57
1.21
1.6
1.2
278.75
286.84
u/ml
0.03
16
87
30
206
1.47
1.18
2.1
1.5
4878.43
176.61
e6/l
0.63
23
163
30
206
1.47
1.18
2.0
1.5
10.77
24.74
e6/l
0.41
22
159
8
38
2.11
1.18
2.3
2.4
—
—
—
0
0
22
142
1.56
1.15
2.2
1.4
124.14
112.46
u/ml
—
7
28
32
225
1.44
1.13
1.8
1.6
—
—
—
0
0
17
103
1.66
1.13
1.5
1.3
871.50
1939.77
e6/l
—
10
73
31
217
1.44
1.12
1.1
1.1
—
—
—
0
0
20
128
1.57
1.09
1.2
1.6
—
—
—
0
0
7
32
2.20
1.08
1.4
1.3
103.00
110.77
%
—
7
26
16
97
1.66
1.07
1.2
1.8
—
—
—
0
0
18
113
1.60
1.06
1.1
1.1
—
—
—
0
0
37
273
1.37
1.02
1.9
1.6
—
—
—
0
0
31
222
1.41
1.01
1.2
1.3
—
—
—
0
0
9
48
1.88
1.00
1.1
1.7
4.37
6.66
u/l
—
9
38
10
54
1.86
0.96
1.0
1.0
—
—
—
0
0
41
311
1.33
0.96
2.0
1.8
—
—
—
0
0
23
158
1.47
0.94
1.6
1.2
—
—
—
0
0
10
56
1.79
0.88
1.0
1.2
—
—
—
0
0
10
56
1.79
0.88
1.0
1.2
—
—
—
0
0
10
56
1.79
0.88
1.2
1.4
76.60
162.87
pmol/l
—
10
56
8
43
1.87
0.87
1.3
1.3
5.97
6.40
mmol/l
—
8
43
16
239
0.66
0.85
1.6
1.5
—
—
—
0
0
15
96
1.57
0.84
2.4
3.8
—
—
—
0
0
95
1105
0.85
0.83
14.3
6.9
—
—
—
0
0
8
46
1.74
0.82
1.5
1.4
—
—
—
0
0
8
46
1.74
0.82
1.5
1.4
—
—
—
0
0
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
8
47
1.71
0.80
1.0
1.1
—
—
—
0
0
24
173
1.40
0.79
1.3
1.2
—
6.86
—
0
13
11
66
1.67
0.79
1.5
1.5
95.45
82.48
umol/l
0.35
11
66
27
199
1.37
0.79
1.2
1.4
—
—
—
0
0
25
183
1.38
0.76
1.3
1.2
—
—
—
0
0
30
227
1.33
0.75
1.0
1.1
1.18
4.78
u/ml
—
5
25
31
237
1.32
0.73
1.3
1.2
—
2.50
—
0
7
43
344
1.26
0.73
2.2
1.9
—
—
—
0
0
11
68
1.62
0.72
1.0
1.2
—
—
—
0
0
9
58
1.56
0.70
1.2
1.7
—
—
—
0
0
5
27
1.86
0.68
1.2
1.3
7.93
9.60
ug/l
—
5
27
14
94
1.50
0.67
4.5
2.6
—
—
—
0
0
8
49
1.64
0.62
1.3
1.8
—
—
—
0
0
8
49
1.64
0.62
1.3
1.8
—
—
—
0
0
0
21
0.00
0.60
0.0
2.2
—
1.98
—
0
9
96
1083
0.87
0.60
5.8
4.6
29.91
32.25
%
1.48
66
726
37
300
1.24
0.59
1.9
2.7
—
—
—
0
0
11
162
0.68
0.59
3.2
3.5
27.45
28.01
u/ml
0.01
11
157
0
23
0.00
0.58
0.0
1.3
—
—
—
0
0
0
23
0.00
0.58
0.0
1.8
—
—
—
0
0
82
720
1.15
0.56
2.2
1.9
—
—
—
0
0
6
38
1.58
0.54
1.3
2.2
74.50
51.07
umol/l
—
6
29
9
60
1.50
0.54
1.7
1.8
—
—
—
0
0
30
241
1.25
0.53
1.4
1.4
—
—
—
0
0
6
97
0.62
0.52
1.3
1.7
—
—
—
0
0
12
84
1.43
0.49
1.9
1.5
—
—
—
0
0
7
48
1.46
0.47
1.1
1.3
1.64
1.54
g/l
—
7
48
20
156
1.29
0.45
1.2
1.8
—
—
—
0
0
9
127
0.71
0.43
1.3
1.4
—
—
—
0
0
9
127
0.71
0.43
1.3
1.4
—
—
—
0
0
11
78
1.41
0.43
1.1
1.3
—
—
—
0
0
16
122
1.32
0.42
1.0
1.1
—
—
—
0
0
5
32
1.57
0.42
1.4
1.1
608.60
1526.81
miu/ml
—
5
32
33
277
1.20
0.41
1.9
2.0
—
—
—
0
0
0
15
0.00
0.41
0.0
1.3
—
—
—
0
0
203
1912
1.08
0.41
5.3
3.9
1.02
1.02
kg/l
0.18
46
261
0
18
0.00
0.40
0.0
1.4
—
—
—
0
0
5
35
1.43
0.39
1.0
1.1
—
—
—
0
0
26
215
1.21
0.38
1.1
1.3
99.51
225.93
miu/ml
—
10
97
5
36
1.39
0.38
2.2
4.7
—
—
—
0
0
11
146
0.75
0.36
1.1
1.6
—
—
—
0
0
11
146
0.75
0.36
1.1
1.6
—
—
—
0
0
22
180
1.23
0.36
2.2
1.6
—
—
—
0
0
9
126
0.71
0.35
1.3
1.4
—
—
—
0
0
9
126
0.71
0.35
1.3
1.4
—
—
—
0
0
12
91
1.32
0.34
1.4
1.4
202822.86
37490.83
e6/l
—
7
53
72
654
1.11
0.33
2.0
1.8
—
—
—
0
0
6
89
0.67
0.33
1.2
1.8
—
—
—
0
0
6
47
1.28
0.32
1.0
1.1
—
—
—
0
0
10
132
0.76
0.32
1.4
1.5
—
—
—
0
0
7
54
1.30
0.30
2.3
1.9
—
—
—
0
0
30
346
0.86
0.30
2.8
1.8
—
—
—
0
0
13
103
1.27
0.28
1.2
1.3
—
—
—
0
0
8
62
1.29
0.28
1.1
1.5
0.97
0.99
g/l
—
8
62
25
214
1.17
0.28
1.2
1.7
—
—
—
0
0
8
65
1.23
0.27
1.6
1.5
—
—
—
0
0
17
203
0.83
0.26
3.2
3.7
23.29
27.53
mg/l
—
7
129
9
73
1.23
0.25
1.0
1.2
—
—
—
0
0
15
123
1.22
0.25
1.3
1.5
—
—
—
0
0
15
123
1.22
0.25
1.1
1.6
—
—
—
0
0
15
123
1.22
0.25
1.3
1.5
—
—
—
0
0
15
123
1.22
0.25
1.3
1.5
—
—
—
0
0
29
254
1.15
0.25
1.2
1.2
—
—
—
0
0
9
75
1.20
0.25
1.0
1.0
—
—
—
0
0
15
124
1.21
0.24
1.3
1.5
—
—
—
0
0
5
38
1.32
0.23
1.0
1.0
—
—
—
0
0
18
211
0.85
0.23
1.6
1.5
—
—
—
0
0
15
125
1.20
0.22
1.3
1.5
—
—
—
0
0
0
12
0.00
0.21
0.0
1.2
—
—
—
0
0
0
13
0.00
0.21
0.0
1.1
—
—
—
0
0
0
13
0.00
0.21
0.0
1.1
—
—
—
0
0
10
80
1.25
0.20
2.3
1.7
—
—
—
0
0
6
48
1.25
0.20
1.5
3.5
—
—
—
0
0
28
250
1.12
0.20
1.5
1.4
—
—
—
0
0
6
50
1.20
0.19
1.2
2.4
—
—
—
0
0
15
127
1.18
0.19
1.9
1.6
—
—
—
0
0
6
51
1.18
0.19
1.2
1.1
—
—
—
0
0
14
120
1.17
0.16
1.1
1.7
—
—
—
0
0
124
1193
1.04
0.15
1.4
1.4
—
—
—
0
0
9
83
1.09
0.14
1.0
1.0
—
—
—
0
0
30
275
1.09
0.14
5.6
3.8
4.00
3.92
mmol/l
0.23
30
270
8
96
0.83
0.13
2.1
1.5
—
—
—
0
0
8
100
0.80
0.13
1.1
1.5
—
—
—
0
0
8
100
0.80
0.13
1.1
1.5
—
—
—
0
0
16
142
1.13
0.12
1.9
1.7
—
—
—
0
0
15
133
1.13
0.12
2.5
3.0
—
2602.91
—
0
11
25
271
0.92
0.11
2.6
1.8
—
—
—
0
0
14
125
1.12
0.10
1.3
1.5
—
—
—
0
0
5
44
1.14
0.10
3.6
1.3
—
—
—
0
0
5
44
1.14
0.10
1.0
1.0
—
—
—
0
0
5
47
1.06
0.09
1.2
1.2
—
—
—
0
0
6
58
1.03
0.08
1.3
2.2
0.22
0.24
e9/l
—
6
51
7
64
1.09
0.08
1.1
1.2
—
—
—
0
0
22
209
1.05
0.04
1.2
1.7
—
—
—
0
0
11
119
0.92
0.04
4.4
2.7
3.93
4.02
mmol/l
0.46
11
119
11
119
0.92
0.04
4.4
2.7
105.00
105.56
mmol/l
0.15
11
119
10
108
0.93
0.03
1.0
1.1
1.49
1.52
g/l
—
10
99
14
147
0.95
0.01
1.1
1.1
—
—
—
0
0
14
139
1.01
0.00
1.6
1.5
—
—
—
0
0
16
155
1.03
0.00
1.3
1.6
—
—
—
0
0
10
95
1.05
0.00
1.1
1.1
—
—
—
0
0
14
135
1.04
0.00
1.1
1.6
—
—
—
0
0
0
8
0.00
0.00
0.0
1.3
—
—
—
0
0
0
8
0.00
0.00
0.0
1.5
—
12.25
—
0
8
0
6
0.00
-0.00
0.0
3.0
—
—
—
0
0
8
82
0.98
-0.00
1.1
1.6
—
—
—
0
0
10
100
1.00
-0.00
1.1
1.1
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
2.7
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.5
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
7
79
0.89
-0.00
1.7
1.6
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
6
61
0.98
-0.00
1.3
2.1
382.67
597.08
e6/l
—
6
52
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
8
82
0.98
-0.00
1.1
1.6
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.1
—
—
—
0
0
6
66
0.91
-0.00
1.0
1.0
249.33
282.11
mg/l
—
6
61
0
7
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.6
—
2.60
—
0
5
8
82
0.98
-0.00
1.1
1.6
—
—
—
0
0
7
73
0.96
-0.00
1.6
1.4
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint E4_HYPERALDO and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| E4_HYPERALDO | 1.424 [1.23, 1.65] | < 0.001 |
| Birth year | 0.993 [0.98, 1.0] | 0.123 |
During the follow-up period (1.1.1998 — 31.12.2019), 414 out of 2277 females with E4_HYPERALDO died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| E4_HYPERALDO | 1.218 [1.05, 1.41] | 0.009 |
| Birth year | 0.985 [0.98, 0.99] | 0.002 |
During the follow-up period (1.1.1998 — 31.12.2019), 357 out of 2005 males with E4_HYPERALDO died.
Mortality risk
Mortality risk for people of age
years, who have E4_HYPERALDO.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.081% | 0.205% |
| 5 | 0.68% | 1.319% |
| 10 | 2.096% | 3.219% |
| 15 | 3.905% | 6.3% |
| 20 | 7.079% | 10.338% |
Relationships between endpoints
↥Index endpoint: E4_HYPERALDO – Hyperaldosteronism
GWS hits: 3
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data